New gene therapy company created and funded by Oxford Science Enterprises, Harrington Discovery Institute and Old College Capital in partnership…
Intravacc - intranasally administered OMV Key mode of action of intranasally administered OMVs. Mucosal route induces both localized and systemic…
Company's flu vaccine, mRNA-1010, met its primary endpoint in Phase 3 trial; separate Phase 1/2 data demonstrated higher HAI titers…
Supply of drug substance manufactured under cGMP supports first-in-human clinical study for RBI-4000 novel self-replicating RNA (srRNA)ALBANY, N.Y., Sept. 13,…
Program will feature executive management plus key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J., Sept. 13, 2023 (GLOBE…
Favorable safety and tolerability profile of OCU400 investigational drug product in RP and LCA subjects to dateClinical study update suggests…
OXFORD, United Kingdom, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the…
Company to provide updated VERSATILE-002 data on combination of PDS0101 and KEYTRUDA®PRINCETON, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) -- PDS…
COPENHAGEN, Denmark, September 13, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today, that it has been awarded another contract…
Company to share updated results from ongoing Phase 1/2 trial of OCU400 for the treatment of Retinitis Pigmentosa and Leber…